Dr.FernandoRuiz

Médico (UPAEP)| Diabetología y Endocrinología Clínica| Máster en Nutrición Clínica y Pediátrica | Miembro ADA, ALAD y SMO . Compartiendo ciencia. 🇲🇽🇪🇸🇺🇾

[JAMA @JAMA_current]

Familial #hypercholesterolemia (FH) is a family of genetic disorders characterized by impaired hepatic clearance of low-density #lipoprotein (LDL) particles, due to pathogenic variants that impair #LDL receptor function.

💡 This JAMA Insights explores FH, including assessment and diagnosis, effective treatments, and management of both homozygous and heterozygous FH. https://t.co/WyCoTAmz28

[Sociedad Española de Patología Digestiva (SEPD) @sepdigestiva]

La enfermedad hepática esteatósica asociada a disfunción metabólica (#MASLD) se caracteriza por la acumulación de grasa en el hígado y puede progresar hacia inflamación hepática y cicatrización del tejido hepático (#fibrosis).

📄 Descubre más en esta Página para Pacientes de JAMA: https://t.co/hSrdSSmddx #Hepatology

[Walter Suárez Carmona @a_fisiolog57853]

Ya he perdido la cuenta de los artículos que se han publicado (y los que quedan) dando vueltas sobre el mismo tema: la importancia de una buena alimentación y del ejercicio físico en combinación con la nueva farmacología para el tratamiento de la obesidad.

Otro más de la lista.

[Scott Isaacs @scottisaacsmd]

Sharing a slide from my recent talk on the future of obesity pharmacotherapy at the 34-lea Congres Național al Societății Române de Endocrinologie in București, România, illustrating the comparative effectiveness of current and emerging obesity medications.

[Antonio García-Hermoso @a_garciahermoso]

La nueva era antiobesidad no va solo de perder peso 💊⚖️

💡 La clave es perder grasa preservando músculo y función 💪

🥇 Preparar
🥈 Combinar fármaco + ejercicio ➡️ fuerza + aeróbico
🥉 Mantener los resultados: peso, metabolismo y función 🏃‍♂️🔁

👇👇
https://t.co/f1jRMXD8kC

[Nature Reviews Endocrinology @NatureRevEndo]

New content online: Strengthening the metabolic alliance: exercise as an essential partner of obesity pharmacotherapy https://t.co/Rm2pPgJz3y

[Cristina Tejera @cristinatejerap]

¿Y si envejecer bien dependiera de la calidad de tus mitocondrias, no de su número?
Nueva revisión en Nature Metabolism @NatMetabolism sobre control de calidad mitocondrial (MQC) y longevidad:

🔧 La célula gestiona sus mitocondrias como una fábrica 🏭 inspecciona, repara y recicla lo defectuoso. Mitofagia + biogénesis = dos mitades del mismo ciclo.
⚖️ Envejecer no es perder mitocondrias, es acumular las malas: masa conservada pero disfuncional.
🩸 Contraintuitivo: el NAD+ en sangre total NO cae de forma universal con la edad.
🏃 El ejercicio aeróbico mejora los marcadores de MQC más que el de fuerza.

📄 https://t.co/jAlTNaxC9m

[Walter Suárez Carmona @a_fisiolog57853]

FISIOPATOLOGÍA DE LA CETOACIDOSIS

Se acompaña de una tabla elaborada por un servidor sobre los tipos de cetoacidosis.

¡¡¡A leer, zagales!!!

Link en mi bio

o

https://t.co/tDebfUacZK

[Christoph Burch @ChristophBurch]

Exercise as a regulator of glymphatic function
https://t.co/DSo5ngJ4NS

[Diabetologia @DiabetologiaJnl]

Hypoglycaemia rates do not differ between genders in the Hypo-METRICS study, but women report more symptomatic hypoglycaemia and a different symptom profile to men https://t.co/yLLNyM5kLF 🔓️

[Walter Suárez Carmona @a_fisiolog57853]

La evidencia actual demuestra que el hipercortisolismo es una causa secundaria de obesidad y diabetes mucho más frecuente de lo que se creía tradicionalmente.

¡¡¡A leer, zagales!!!

Link en mi bio

o

https://t.co/wDLwPdikPL

[Cristina Tejera @cristinatejerap]

¿ La insulina te hace aumentar de peso?
@NatureRevEndo
Esta revisión plantea una idea incómoda👉 La hiperinsulinemia basal crónica podría no ser solo un marcador de resistencia a la insulina, sino un actor que favorezca la obesidad y la enfermedad cardiometabólica.

Diferenciar los picos fisiológicos tras las comidas de la hiperinsulinemia mantenida puede cambiar nuestra forma de entender la enfermedad.

Importante no sobreinterpretar el efecto ➡️ el principal motor de la obesidad sigue siendo el ambiente obesogénico.

Guess N, et al. Nat Rev Endocrinol. 2026
🔗 https://t.co/cVIbzi5YeW

[NEJM @NEJM]

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one in three adults worldwide, yet many cases remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening?

In the latest episode of the Beyond Journal Club podcast from @COREIMpodcast and NEJM Group, the hosts unpack the evolving language of steatotic liver disease and discuss two major trials: MAESTRO-NASH studying resmetirom, the first FDA-approved liver-directed therapy for MASH, and ESSENCE, evaluating semaglutide in biopsy-confirmed disease.

Listen to the full episode to understand where the field is headed, which patients deserve closer attention, and how metabolic liver disease is increasingly becoming part of everyday primary care and hospital medicine: https://t.co/xJSWsDdsm6

Further reading: 
📄 Original Article by S.A. Harrison et al.: A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (MAESTRO-NASH) https://t.co/sp7Co5pDwr
📄 Original Article by A.J. Sanyal et al.: Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) https://t.co/9sdR9gGUOE

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

While many benefits of #obesity medications are mediated by weight loss, accumulating evidence indicates important weight loss-independent effects, particularly with #GLP-1 receptor agonist-based therapies https://t.co/IFPyEU8bKn
#weightloss

[AHA Science @AHAScience]

Published today, AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (HF) (2026) https://t.co/YDuE4stb5s

✍🏼 @MinnowWalsh @KarenSliwa @amibanerjee1 @BiykemB @akshaydesaimd @DukeHFDoc @MKIttlesonMD @lamcardio @WilfriedMullens @NutritionHF

📷 Trajectories of HF.

An individual’s HF journey starts left to right, and quality of life or exercise capacity and prognosis become poor as HF stage advances. Every stage carries certain risk of sudden death.

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

New—Endocrine–neuropsychological interplay underpinning maternal postpartum depression https://t.co/kL27Pjv4rs
#postpartum #depression

[Ahmed Bennis MD 🫀 @drbennisahmed]

How Obesity Contributes to Chronic Kidney Disease (CKD)
⚡ Adipocyte storage gets exceeded → fatty acids leak into the bloodstream and accumulate in ectopic tissue, including perirenal & renal sinus fat

🔺 Hormonal shift: activates RAAS + sympathetic nervous system

[🔬 RicardoMontes @_MCRicardo_]

Polyphenols and Cardiovascular Diseases: Molecular Insights & Nutraceutical Advances

▶️ Polyphenols, a structurally diverse class of bioactive compounds widely distributed in plant-based foods, confer potent redox-modulating properties.

▶️ Dietary polyphenols exert cardioprotective effects through antioxidant, anti-inflammatory, & endothelial-modulating mechanisms.

✅️ This review provides an updated and integrative analysis of the molecular mechanisms underlying the cardioprotective effects of polyphenols, emphasizing their role in endothelial function and nitric oxide bioavailability

https://t.co/J3MWE1EBTa @HealthyFellow @JuhanaHarju
@tatiann69922625

[Michael Weintraub, MD @MWeintraubMD]

💉 Survodutide, a dual GLP-1/glucagon agonist, with Phase 3 results specifically in those with metabolic-associated steatotic liver disease (MASLD).

⬇️ 84% of survodutide group met primary endpoint of >30% liver fat content reduction by MRI, compared to 24% of placebo.

⬇️ Survodutide group had 12% weight reduction vs. 1% with placebo.

🔑 Glucagon agonism likely has direct liver benefits, independent of weight loss

📊 SYNCHRONIZE-MASLD published in Nature Medicine: https://t.co/ZOJ1HILgAH

[🔬 RicardoMontes @_MCRicardo_]

Association between advanced glycation end products (AGEs) and bone mineral density (BMD) in Mexican population

⚠️ Elevated serum AGEs levels are associated w/lower BMD over time, particularly among women. These findings suggest a potential role of AGEs in bone deterioration & their relevance in clinical risk assessment.

Highlights:

▶️ Higher serum AGEs are linked to lower BMD over time.

▶️ Associations were strongest among women aged 45 years & older.

▶️ Men aged 45 years & older also showed lower hip and neck BMD w/high AGEs.

▶️ No significant associations were found in men younger than 45 years.

▶️ AGEs may contribute to bone deterioration & aid clinical risk assessment.

https://t.co/cA0MYIlHQw @DHPSP